Stem Cell Clinic

Stem Cells Market to Hit $23.7 Billion by 2030 at 9.1% CAGR … – GlobeNewswire

By adminNovember 25, 2023Adult Stem Cells

Burlingame, Nov. 21, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Stem Cells Market size was valued at US$ 12.9 Billion in 2023 and is expected to surpass US$ 23.7 Billion by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 9.1% from 2023 to 2030. Strong product pipelines of therapies based on stem cells and a huge patient population base can help propel growth of the global stem cells market. Government funding to accelerate research on stem cells further strengthens the growth of the market. For instance, in February 2022, the government of India set up state-of-the-art stem cell research facilities in 40 leading health research and educational institutions. The government has also spent US$ 80.0 Million through the Indian Council of Medical Research (ICMR) since 2019 on stem cell research projects.

Market Drivers

Strategic activities by key market players to strengthen their product portfolios will further offer lucrative opportunities in the global stem cells market over the forecast period. For instance, in February 2022, Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases, announced that they have expanded their strategic alliance to pursue the development of multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs. The program will utilize Immatics N.V.s proprietary gamma delta T cell-derived, allogeneic Adoptive Cell Therapy (ACT) platform, called ACTallo, and a suite of next-generation technologies developed by Bristol Myers Squibb Company.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4222

Key Market Takeaways:

The global stem cells market is expected to exhibit a CAGR of 9.1% during the forecast period due to the large number of applications that stem cell therapy offers across the healthcare and disease spectrum. For instance, according to an article shared by amfAR, The Foundation for AIDS Research (An organization dedicated to ending the global AIDS epidemic through innovative research), HIV-resistant stem cells, when induced in suffering patients, can be permanently cured of the disease upon receiving a bone marrow transplant.

Among application, the adult stem cells segment is dominant due to the establishment of new companies regarding the research of adult cell stems across the globe. For instance, on May 25, 2023, Therapeutic Solutions International (TSOI), a company focused on immune modulation for the treatment of several specific diseases, announced the creation of CTE Biologics, Inc. as a subsidiary company dedicated to commercializing the JadiCell adult stem cell platform for the treatment of chronic traumatic encephalopathy.

Among region, North America is expected to be dominant in the growth of the global stem cells market over the forecast period. In October 2022, Pluristyx, a privately held biotechnology company based in Seattle, U.S., panCELLa, a company focused on therapeutic cell-focused Platform Technologies and based in Ontario, Canada, and Implant Therapeutics, a company that specializes in cell-based therapies and based in Maryland, U.S., announced a definitive merger agreement to streamline access to genetically modified stem cells for clinical development.

Key players operating in the global stem cells market are Advanced Cell Technology, Inc., Angel Biotechnology Holdings PLC, Biotricity, Lineage Cell Therapeutics, Inc., BrainStorm Cell Limited., CIRM, Celgene Corporation (A subsidiary of Bristol-Myers Squibb Company), Takara Bio Inc., Cellular Engineering Technologies., Cytori Therapeutics Inc., and STEMCELL Technologies.

Request Customization: https://www.coherentmarketinsights.com/insight/request-customization/4222

Market Key Developments

Inorganic strategies like mergers, acquisitions, and partnership agreements are also enhancing growth of the global stem cells market. For instance, in December 2022, Kite (A subsidiary of Gilead Sciences, Inc.) acquired Tmunity Therapeutics, Inc., a private, clinical-stage biotechnology company, focused on transforming the future of CAR-T therapies by developing the next generation of engineered T-cell therapies and innovative manufacturing processes and technologies to pursue next-generation CAR-T-Cell therapy advancements in cancer.

Market Restraint

The inability of certain stem cell therapies to produce substantial evidence, can restrain growth of the global stem cells market. In December 2022, The National Medical Commission (NMC), an Indian regulatory body of 33 members which regulates medical education and medical professionals, directed doctors not to use stem cell therapy for treating autism, citing insufficient evidence and lack of efficacy.

This restraint can be overcome by following the correct stem cell therapy only as per the guidance and recommendations of doctors or healthcare providers.

Market Opportunity

The increase in growth strategies like investments by key market players is estimated to cause the growth of the global stem cells market over the forecast period. For instance, on June 23, 2023, Calidi Biotherapeutics, a clinical-stage immuno-oncology company, announced a commitment of US$ 25 Million in series B funding to advance stem cell-based platforms for the delivery and potentiation of oncolytic viruses to treat cancer.

Buy this Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4222

Detailed Segmentation:

Find more related trending reports below:

Protein Sequencing Market, By Technology (Edman Degradation, Mass Spectrometry, Others), By Product (Instruments, Reagents, Kits & Consumables, Software & Services), By Application (Academic Research, Clinical Diagnosis, Biopharmaceuticals, Others), By End-user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Red Biotechnology Market, By Product Type (Biopharmaceuticals, Biosimilars, Gene Therapy, Tissue Engineering, Cell Therapy), By Application (Drug Discovery & Development, Animal Biotechnology, Environmental Biotechnology, Medical Biotechnology, Industrial Biotechnology, Agricultural Biotechnology, Others), By End User (Pharmaceutical & Biopharmaceutical Companies, Research Institutes, Biotechnology Industry, Hospitals & Diagnostic Centers, Academic Institutions), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Bioprocess Validation Market, By Test Type (Extractable Testing Services, Microbiological Testing Services, Physiochemical Testing Services, Integrity Testing Services, and Others (Compatibility Testing Services and Others)), By Process Component (Filter Elements, Media containers and bags, Freezing And Thawing Process Bags, Bioreactors, Transfer Systems, and Others (Mixing Systems and Others)), By End User (Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations, Academic and Research Institutes, and Other (Clinical Research Organizations and Others)), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Stem Cell Manufacturing Market, By Type (Product and Services), By Application (Stem Cell Therapy, Drug Discovery and Development, and Stem Cell Banking), By End-User (Pharmaceutical and Biotechnology Companies & CRO, Cell Banks and Tissue Banks, and Others), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

More:
Stem Cells Market to Hit $23.7 Billion by 2030 at 9.1% CAGR ... - GlobeNewswire

Stem Cell Therapy Developed in Korea Begins Treatment for … – PharmiWeb.com

By adminNovember 25, 2023Adult Stem Cells

SEOUL, South Korea, November 21, 2023 (Newswire.com) - Korea's leading adult stem cell research institute, Biostar Stem Cell Research Institute (Director: Dr. Jeongchan Ra), announced on the 20th that a regenerative medicine technology that treats Parkinson's disease by administering autologous fat-derived stem cells cultured using patented technology into the intravenous and spinal cord cavity has been approved by the Japanese Ministry of Health and Welfare and will begin treatment at the Shinjuku Clinic in Tokyo in December.

The approved stem cell treatment protocol involves administering 150 to 250 million fat-derived stem cells intravenously and 50 million cells into the spinal cord cavity five times at intervals of two to four weeks. The stem cells are either obtained from the Biostar Stem Cell Research Institute in Korea or from JASC, a Japanese affiliate.

The approval of stem cell treatment for Parkinson's disease marks a significant milestone in the clinical application of stem cells by the Biostar Stem Cell Research Institute, which began its research in 2008. The institute has previously received stem cell therapies for degenerative arthritis, severe lower extremity ischemia, and autoimmune diseases, administrated through intraarticular, intramuscular, and intravenous routes, respectively. The intravenous and spinal cord cavity administration of stem cells for Parkinsons disease further demonstrates the versatility and safety of Biostars stem cell culture technology.

Stem cells vary greatly in safety and effectiveness depending on the culture method, highlighting the importance of rigorous quality management. The Biostar Stem Cell Research Institutes two-decade-long research on stem cell culture and treatment technologies, including the recently approved Parkinsons disease therapy, holds promise for developing new avenues for treating neurological disorders. The specialized culture media developed by the Biostar Stem Cell Research Institute, exclusively manufactured and supplied by its affiliate Nature Cell, plays a crucial role in enhancing the effectiveness and safety of these therapies.

The Biostar Stem Cell Research Institute is committed to expanding treatment-approved hospitals across Japan and intensifying global outreach, aiming to make Japan a destination for Parkinson's disease patients worldwide to regain their health.

Parkinsons disease affects an estimated 10 million people worldwide, with a rapidly growing prevalence, and remains an incurable condition without a definitive treatment.

Herim Park Marketing Manager herim16@stemcellbio.com +81-75-662-7171

Original Source: Stem Cell Therapy Developed in Korea Begins Treatment for Parkinson's Disease Patients Worldwide in Japan

See the original post here:
Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com

BrainStorm Cell Therapeutics Announces In-Person Meeting with … – PR Newswire

By adminNovember 25, 2023Adult Stem Cells

Meeting will take place on December 6; Company plans to seek Special Protocol Assessment (SPA)

NEW YORK, Nov. 20, 2023 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the US Food & Drug Administration (US FDA) has granted the company a meeting to discuss the regulatory path forward for NurOwn in amyotrophic lateral sclerosis (ALS). The meeting is scheduled to take place on December 6, 2023. Brainstorm will discuss plans for a Special Protocol Assessment (SPA) with the FDA to agree on the overall protocol design for a confirmatory Phase 3 trial in ALS.

"We are pleased that the FDA has granted this expedited in-person meeting to discuss the best path forward for NurOwn for ALS," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "Our proposed plan is to conduct a confirmatory Phase 3b trial and it is important that we are aligned with the Agency on the expected requirements for re-submitting a Biologics License Application. We believe that reaching an agreement through a SPA on the overall protocol design and the adequacy to address the requirements for marketing approval will be a key step to position the company for success and to potentially de-risk the program. We are grateful for the FDA's support and quick response in granting this meetingas we remain committed to our goal of making NurOwn available to the ALS community."

AboutNurOwn

The NurOwn technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are harvested from each person with ALS and are manufactured using an innovative and proprietary process to secrete neurotrophic factors to target specific neurodegenerative diseases. The lead program for NurOwn is for the treatment of ALS.BrainStorm's long-term commitment to ALS is demonstrated in preclinical research and a series of clinical studies, all of which have been published in peer-reviewed journals.

The NurOwn clinical program has generated valuable insights into the pathology of ALS, as well as disease progression and treatment. Since the initial Phase 3 readout, BrainStorm has shared the full dataset through rigorous peer-reviewed analysis, including: quantification of Floor Effect, which had been noted, but never before explored in depth; evaluation of multiple pre-specified biomarkers, collected at seven different points across 20 weeks during the trial, allowing a longitudinal view; and analysis of genetic data, which represents one of the first ALS trials to prospectively invoke pharmacogenomic analysis of clinical outcome, offering great promise for the development of future treatments for ALS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. BrainStorm holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989), and another grant from the ALS Association and I AM ALS. BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive MS and was supported by a grant from the National MS Society (NMSS).

Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital.

BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

CONTACTS

JohnMullaly LifeSci Advisors, LLC Phone: +1 617-429-3548 [emailprotected]

Logo - https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg

SOURCE Brainstorm Cell Therapeutics Ltd.

More here:
BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire

Skull bone marrow channels as immune gateways to the central … – Nature.com

By adminNovember 25, 2023Adult Stem Cells

Vajkoczy, P., Laschinger, M. & Engelhardt, B. 4-integrin-VCAM-1 binding mediates G-proteinindependent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J. Clin. Invest. 108, 557565 (2001).

Article CAS PubMed PubMed Central Google Scholar

Steinman, L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4, 510518 (2005).

Article CAS PubMed Google Scholar

Mrdjen, D. et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity 48, 380395 (2018).

Article CAS PubMed Google Scholar

Hove, H. V. et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. Nat. Neurosci. 22, 10211035 (2019).

Article PubMed Google Scholar

Fitzpatrick, Z. et al. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature 587, 472476 (2020).

Article CAS PubMed PubMed Central Google Scholar

Dani, N. et al. A cellular and spatial map of the choroid plexus across brain ventricles and ages. Cell 184, 30563074 (2021).

Article CAS PubMed PubMed Central Google Scholar

Sanmarco, L. M. et al. Gut-licensed IFN+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes. Nature https://doi.org/10.1038/s41586-020-03116-4 (2021).

Croese, T., Castellani, G. & Schwartz, M. Immune cell compartmentalization for brain surveillance and protection. Nat Immunol. https://doi.org/10.1038/s41590-021-00994-2 (2021).

Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337341 (2015).

Article CAS PubMed PubMed Central Google Scholar

Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212, 991999 (2015).

Article CAS PubMed PubMed Central Google Scholar

Absinta, M. et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. Elife 6, e29738 (2017).

Article PubMed PubMed Central Google Scholar

Schlger, C. et al. Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. Nature 530, 349353 (2016).

Article PubMed Google Scholar

Ringstad, G. & Eide, P. K. Cerebrospinal fluid tracer efflux to parasagittal dura in humans. Nat. Commun. 11, 354 (2020).

Article CAS PubMed PubMed Central Google Scholar

Rustenhoven, J. et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell https://doi.org/10.1016/j.cell.2020.12.040 (2021).

Merlini, A. et al. Distinct roles of the meningeal layers in CNS autoimmunity. Nat. Neurosci. 25, 887899 (2022).

Article CAS PubMed Google Scholar

Li, Z. et al. Blockade of VEGFR3 signaling leads to functional impairment of dural lymphatic vessels without affecting autoimmune neuroinflammation. Sci. Immunol. 8, eabq0375 (2023).

Article CAS PubMed Google Scholar

Herisson, F. et al. Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat. Neurosci. 21, 12091217 (2018).

Article CAS PubMed PubMed Central Google Scholar

Cai, R. et al. Panoptic imaging of transparent mice reveals whole-body neuronal projections and skullmeninges connections. Nat. Neurosci. https://doi.org/10.1038/s41593-018-0301-3 (2018).

Cugurra, A. et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science 373, eabf7844 (2021).

Article CAS PubMed PubMed Central Google Scholar

Brioschi, S. et al. Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders. Science 373, eabf9277 (2021).

Article CAS PubMed PubMed Central Google Scholar

Yao, H. et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature 560, 5560 (2018).

Article CAS PubMed PubMed Central Google Scholar

Mazzitelli, J. A. et al. Cerebrospinal fluid regulates skull bone marrow niches via direct access through dural channels. Nat. Neurosci. https://doi.org/10.1038/s41593-022-01029-1 (2022).

Pulous, F. E. et al. Cerebrospinal fluid can exit into the skull bone marrow and instruct cranial hematopoiesis in mice with bacterial meningitis. Nat. Neurosci. 25, 567576 (2022).

Article CAS PubMed PubMed Central Google Scholar

Kolabas, Z. I. et al. Distinct molecular profiles of skull bone marrow in health and neurological disorders. Cell 186, 37063725 (2023).

Article CAS PubMed PubMed Central Google Scholar

Lachkar, S. et al. The diploic veins: a comprehensive review with clinical applications. Cureus 11, e4422 (2019).

PubMed Google Scholar

Garca-Gonzlez, U. et al. The diploic venous system: surgical anatomy and neurosurgical implications. Neurosurg. Focus 27, E2 (2009).

Article PubMed Google Scholar

Alarfaj, A. et al. Magnetic resonance imaging analysis of human skull diploic venous anatomy. Surg. Neurol. Int. 12, 249 (2021).

Article PubMed PubMed Central Google Scholar

Grneboom, A. et al. A network of trans-cortical capillaries as mainstay for blood circulation in long bones. Nat. Metab. 1, 236250 (2019).

Article PubMed PubMed Central Google Scholar

Raggatt, L. J. & Partridge, N. C. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285, 2510325108 (2010).

Article CAS PubMed PubMed Central Google Scholar

Wang, Y. et al. Early developing B cells undergo negative selection by central nervous system-specific antigens in themeninges. Immunity https://doi.org/10.1016/j.immuni.2021.09.016 (2021).

Schafflick, D. et al. Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges. Nat. Neurosci. 24, 12251234 (2021).

Article CAS PubMed Google Scholar

Niu, C. et al. Identification of hematopoietic stem cells residing in the meninges of adult mice at steady state. Cell Rep. 41, 111592 (2022).

Article CAS PubMed Google Scholar

Ringstad, G. & Eide, P. K. Molecular trans-dural efflux to skull bone marrow in humans with cerebrospinal fluid disorders. Brain https://doi.org/10.1093/brain/awab388 (2021).

Katayama, Y. et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124, 407421 (2006).

Article CAS PubMed Google Scholar

Maryanovich, M. et al. Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche. Nat. Med. 24, 782791 (2018).

Article CAS PubMed PubMed Central Google Scholar

Gao, X. et al. Nociceptive nerves regulate haematopoietic stem cell mobilization. Nature 589, 591596 (2021).

Article CAS PubMed Google Scholar

Moalem, G. et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5, 4955 (1999).

Article CAS PubMed Google Scholar

Russo, M. V., Latour, L. L. & McGavern, D. B. Distinct myeloid cell subsets promote meningeal remodeling and vascular repair after mild traumatic brain injury. Nat. Immunol. 19, 442452 (2018).

Article CAS PubMed PubMed Central Google Scholar

Mastorakos, P. et al. Temporally distinct myeloid cell responses mediate damage and repair after cerebrovascular injury. Nat. Neurosci. 24, 245258 (2021).

Article CAS PubMed PubMed Central Google Scholar

Salvador, A. F. M. & Kipnis, J. Immune response after central nervous system injury. Semin. Immunol. https://doi.org/10.1016/j.smim.2022.101629 (2022).

Courties, G. et al. Ischemic stroke activates hematopoietic bone marrow stem cells. Circ. Res. 116, 407417 (2015).

Article CAS PubMed Google Scholar

Hadjikhani, N. et al. Extraaxial inflammatory signal in parameninges in migraine with visual aura. Ann. Neurol. 87, 939949 (2020).

Article PubMed PubMed Central Google Scholar

Klein, R. S. et al. Neuroinflammation during RNA viral infections. Annu. Rev. Immunol. 37, 7395 (2019).

Article CAS PubMed PubMed Central Google Scholar

Mura, S. R., Farez, M. F. & Quintana, F. J. The immune response in multiple sclerosis. Annu. Rev. Pathol. Mech. Dis. 17, 121139 (2022).

Article Google Scholar

Shi, K. et al. Bone marrow hematopoiesis drives multiple sclerosis progression. Cell 185, 22342247 (2022).

Article CAS PubMed Google Scholar

Giladi, A. et al. Cxcl10+ monocytes define a pathogenic subset in the central nervous system during autoimmune neuroinflammation. Nat. Immunol. 21, 525534 (2020).

Article CAS PubMed Google Scholar

Wilcox, J. A., Li, M. J. & Boire, A. A. Leptomeningeal metastases: new opportunities in the modern era. Neurotherapeutics https://doi.org/10.1007/s13311-022-01261-4 (2022).

Sipkins, D. A. et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435, 969973 (2005).

Article CAS PubMed PubMed Central Google Scholar

Boire, A. et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168, 11011113 (2017).

Article CAS PubMed PubMed Central Google Scholar

Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326341 (2017).

Article CAS PubMed PubMed Central Google Scholar

Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934941 (2022).

Article CAS PubMed PubMed Central Google Scholar

Chen, X. & Holtzman, D. M. Emerging roles of innate and adaptive immunity in Alzheimers disease. Immunity 55, 22362254 (2022).

Article CAS PubMed Google Scholar

Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimers disease. N. Engl. J. Med. 367, 795804 (2012).

Article CAS PubMed PubMed Central Google Scholar

Barthlemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimers disease. Nat. Med. 26, 398407 (2020).

Article PubMed PubMed Central Google Scholar

Nation, D. A. et al. Bloodbrain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat. Med. 25, 270276 (2019).

Link:
Skull bone marrow channels as immune gateways to the central ... - Nature.com

UCI achieves rare trifecta: Three scientists receive New Innovator … – UCI News

By adminNovember 25, 2023Adult Stem Cells

Irvine, Calif., Sept. 30, 2013 UC Irvine scientists Aaron Esser-Kahn, Sunil Gandhi and Ali Mortazavi have been named recipients of the prestigious 2013 National Institutes of Health Directors New Innovator Awards.

The highly selective award program supports projects by early-career researchers that show potential to transform scientific fields and accelerate the translation of research into new ways to improve human health.

Esser-Kahn, Gandhi and Mortazavi will each receive $1.5 million for five years to fund their projects. They are among 41 investigators to receive the award; UC Irvine joins Stanford University, UC San Francisco and UC Berkeley as the only institutions to have three honorees.

Its rare that an institution is home to more than one New Innovator recipient in one year, and that UC Irvine has three is a testament to the robust environment that encourages our early-career research faculty members, said John Hemminger, vice chancellor of research. Aaron, Sunil and Ali are exceptional scientists, and we are proud that the NIH, in this age of sequestration, has chosen to support their visionary work.

Esser-Kahnis an assistant professor of chemistry in the School of Physical Sciences. The New Innovator Award will boost his efforts to understand vaccine effectiveness by looking at structure of its molecular components. By uncovering this molecular code, Esser-Kahn believes this research can aid in the development of safer, more targeted vaccines.

Gandhiis an assistant professor of neurobiology & behavior in the School of Biological Sciences. With the award, he will study whether transplanting a type of nerve cell that dampens activity can rewire neural pathways in the adult brain, a process called neuroplasticity. Findings could help repair damage caused by traumatic brain injury, stroke or neurodegenerative disease. In addition, methods for reactivating neuroplasticity might eventually be used to enhance behavioral therapies for psychiatric disorders such as autism and schizophrenia. Earlier this year, Gandhi was named one of 15Searle Scholars, an award which recognizes innovative biomedical and chemistry research by young faculty.

Mortazaviis an assistant professor of developmental & cell biology in the School of Biological Sciences. His project will explore how DNA codes the precise activities of genes involved with development. His lab will create methods to measure how this gene expression is affected by changes in the organization of DNA in embryonic stem cells as they differentiate into neurons and cardiac muscle cells. Mortazavi believes his research will identify fundamental principles of gene regulation as well as the specific DNA elements critical to stem cell differentiation.

The New Innovator Award highlights two important goals of the NIH by stimulating highly original research and supporting promising new investigators. In 2013, under its High Risk-High Reward program, the NIH is awarding 12 Pioneer Awards, 41 New Innovator Awards, 10 Transformative Research Awards and 15 Early Independence Awards. The total funding, which represents contributions from the NIH Common Fund and multiple NIH institutes and centers, is approximately $123 million.

More information on the NIH High Risk-High Reward Research Program is at:http://commonfund.nih.gov/highrisk/.

About the University of California, Irvine: Located in coastal Orange County, near a thriving employment hub in one of the nations safest cities, UC Irvine was founded in 1965. One of only 62 members of the Association of American Universities, its ranked first among U.S. universities under 50 years old by the London-based Times Higher Education. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by ChancellorMichael Drakesince 2005, UC Irvine has more than 28,000 students and offers 192 degree programs. Its Orange Countys second-largest employer, contributing $4.3 billion annually to the local economy.

About the National Institutes of Health (NIH): NIH, the nations medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visitwww.nih.gov.

Media access: UC Irvine maintains an online directory of faculty available as experts to the media athttp://communications.uci.edu/for-journalists/experts/. Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UC Irvine faculty and experts, subject to availability and university approval. For more UC Irvine news, visitwp.communications.uci.edu. Additional resources for journalists may be found atcommunications.uci.edu/for-journalists.

See the article here:
UCI achieves rare trifecta: Three scientists receive New Innovator ... - UCI News

Illuminating Hope: Whole-Eye Transplant – The Nation

By adminNovember 25, 2023Adult Stem Cells

In the annals of medical history, a groundbreaking achievement recently unfolded at NYU Langone Health in New Yorka feat destined to redefine the trajectory of medical sciences and shed light on the hopes of countless individuals living without the gift of sight. The remarkable journey of Aaron James, a resilient 46-year-old military veteran from Arkansas, epitomises this historic milestone. Enduring a life-altering work-related electrical accident that mutilated the left side of his face, including his left eye, nose, and mouth, Aaron became the first recipient of this extraordinary whole-eye transplant.

The surgical team, spearheaded by Dr. Eduardo Rodriguez, meticulously executed a 21-hour surgery, initially aimed at amalgamating the eyeball for aesthetic enhancement within a partial face transplant. However, this unprecedented leap of medical science burgeoned into an incandescent ray of hope for vision restoration. Despite the present lack of direct communication between the transplanted eye and Aarons brain through the optic nerve, the grafted eye exhibits vital signs of health, showcasing well-functioning blood vessels and a promising retina. The pioneering approach of integrating adult stem cells from the donors bone marrow into the optic nerve during the transplant ignites the flame of potential healing and paves the way for future breakthroughs in vision restoration. Even though immediate restoration of sight remains elusive, the procedures success is a testament to the relentless pursuit of innovation, the resilience of human spirit, and the uncharted possibilities of medical science.

Aarons journey embodies not just a personal odyssey but a collective pursuit of knowledge, echoing the sentiment that even in uncertainty, theres hope, learning, and the potential for groundbreaking discoveries. His altruistic outlook, aiming not solely for personal recovery but to pioneer a path for future advancements, encapsulates the quintessence of human resilience and the quest for scientific progress. This historic achievement stretches far beyond the individual triumph of Aaron James. Its a testament to the unwavering human resolve to traverse uncharted territories, pushing the frontiers of medical science to envision a future where the visually impaired may one day perceive the world anew. This pioneering feat in medical science unravels a tapestry of hope, painting a future where the once unattainable prospect of sight restoration might become a reality for countless individuals. The indelible mark of this unprecedented accomplishment is etched not just in medical history but in the hearts and hopes of humanity, illuminating a path toward a brighter, more visually inclusive world This achievement serves as a clarion call to the scientific community, prompting a deeper exploration into the intricate connection between the eye and the brain. The present limitations in direct communication between the transplanted eye and the recipients brain through the optic nerve may not only be a hurdle but also a portal to a broader understanding of nerve regeneration and connectivity. It beckons neuroscientists and ophthalmologists to delve into uncharted territories, exploring methods to bridge this communication gap, with the ultimate goal of restoring sight.

The inclusion of adult stem cells during the transplant signifies a progressive step in regenerative medicine. This novel approach, while not yet resulting in restored vision, lays the groundwork for potential healing and creates a roadmap for future endeavors in vision restoration. The possibility of stimulating nerve regeneration and fostering communication between the eye and the brain through innovative medical interventions offers a glimmer of hope for the future. The essence of this historic feat reverberates beyond the confines of a successful surgery. It resonates with the potential it holds for the millions globally who grapple with visual impairment. The aspiration to grant the gift of sight to those living in darkness becomes a beacon of hope, kindling a new chapter in medical innovation. This pioneering surgery becomes a catalyst for an array of future endeavors. The prospect of connecting nerve networks in the brain to sightless eyes through the insertion of electrodes represents just one pathway being explored. The collective effort of various research teams worldwide in finding innovative methods to restore vision serves as a testament to the unwavering quest for progress. The collaborative synergy among scientists, surgeons, and researchers paints a tapestry of possibilities that could potentially illuminate the lives of the visually impaired.

This historic surgery not only symbolises a breakthrough but also serves as a gateway to potential advancements in the restoration of vision. Despite the immediate challenges in communicating between the transplanted eye and the brain, the inclusion of adult stem cells during the transplant hints at future possibilities in healing and potential restoration of sight. The successful integration of the eye into the recipients facial structure, despite the current lack of vision, underscores the resilient spirit of scientific exploration. This milestone is a stepping stone towards understanding nerve regeneration and bridging the connection between the eye and the brain. While immediate sight restoration might be challenging, this achievement kindles a spark of optimism for future advancements in the restoration of vision for individuals who have lost it due to accidents or optic nerve damage.

In conclusion, the worlds inaugural whole-eye transplant at NYU Langone Health stands as an emblem of human determination, resilience, and the relentless pursuit of progress. Beyond the surgical success lies a canvas brimming with potentialthe potential to unveil vistas of sight for those shrouded in darkness, the potential to script a new chapter in medical history, and the potential to transform the dreams of many into tangible realities.

Dr Asif Channer The writer is a Public Health professional and freelance columnist. He can be contacted at dremergency bwp@hotmail.com

BrainStorm Cell Therapeutics Announces Third quarter 2023 … – PR Newswire

By adminNovember 17, 2023Adult Stem Cells

Conference call and webcast at 8:30 a.m. Eastern Time today

NEW YORK, Nov. 14, 2023 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

"We are committed to our goal of making NurOwn available to the ALS community and intend to work with the FDA to agree on a path forward," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We acknowledge that approval will require a confirmatory Phase 3b trial and look forward to meeting with the FDA to align on the details. The recently announced strategic realignment is a necessary step to conserve and refocus resources, and we believe this will position us better to accelerate our ALS development program."

Stacy Lindborg, Ph.D., co-CEO BrainStorm commented, "We believe we have generated a compelling body of clinical data that support the utility of NurOwn in ALS. We intend to harness the learnings from our prior studies to conduct a Phase 3b trial as efficiently as possible. We will also continue to engage with the academic community to share new data with our goal of leveraging the latest results to contribute to new insights into ALS and NurOwn."

Third quarter 2023 and Recent Highlights

Clinical and regulatory

Corporate

Financial Results for the Quarter Ended September 30, 2023

Cash, cash equivalents, and short-term bank deposits were approximately $1.4 million as of September 30, 2023, compared to $3 million as of December 31, 2022.

Research and development expenses for the three months ended September 30, 2023 and 2022 were approximately $3.3 million and $3.8 million, respectively.

General and administrative expenses for the three months ended September 30, 2023 and 2022 were approximately $2.7 million and $3.1 million, respectively.

Net loss for the three months ended September 30, 2023 was approximately $1.2 million, as compared to a net loss of approximately $6.9 million for the three months ended September 30, 2022.

Net loss per share for the three months ended September 30, 2023 and 2022 was $0.03 and $0.19, respectively.

For more details on the financials, including results for the 9 month period ended September 30, 2023, refer to Form 10Q filed with the SEC.

Conference Call and Webcast, 8:30 a.m. Eastern Time Today

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free:

888-506-0062

International:

973-528-0011

Access Code:

944879

Webcast URL:

https://rb.gy/875eq4

Those interested in listening to webcast may do so by using the link above or by visiting the "Investors & Media" page of BrainStorm's website at

https://ir.brainstorm-cell.com/overviewand clicking on the webcast link.

The replay of the conference call can do so by dialing the numbers below and will be available untilNovember 28, 2023.

Replay Numbers:

Toll Free:

877-481-4010

International:

919-882-2331

Replay Passcode:

49431

AboutNurOwn

About BrainStorm Cell Therapeutics Inc.

Notice Regarding Forward-Looking Statements

CONTACTS

Investor Relations: John Mullaly LifeSci Advisors, LLC Phone: +1 617-429-3548 [emailprotected]

Media: Lisa Guiterman Phone: +1 202-330-3431 [emailprotected]

BRAINSTORM CELL THERAPEUTICSINC. AND SUBSIDIARIES

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

(Except share data)

September30,

December31,

2023

2022

Unaudited

Audited

U.S.$inthousands

ASSETS

Current Assets:

Cash and cash equivalents

1,222

772

Short-term deposit (Note 4)

196

2,211

Other accounts receivable

Prepaid expenses and other current assets

Total current assets

1,539

3,106

Long-Term Assets:

Prepaid expenses and other long-term assets

Operating lease right of use asset (Note 6)

3,370

4,389

Property and Equipment, Net

752

933

Total Long-Term Assets

4,143

5,345

Total assets

5,682

8,451

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities:

Accounts payables

3,926

More:
BrainStorm Cell Therapeutics Announces Third quarter 2023 ... - PR Newswire

Sight Care Reviews: Supplement Scam or Safe EyeSight Formula to … – Snoqualmie Valley Record

By adminNovember 17, 2023Adult Stem Cells

Sight Care is a natural, holistic formula for those seeking healthier vision. The dietary supplement ingredients are backed by clinical trials showing that the formula optimizes eye health. Sight Care formulation addresses impairment of the eyes by targeting the conditions root causes. Therefore, the vision support formula provides a safer and relatively affordable solution without requiring invasive surgery.

Apart from stimulating the nervous system, Sight Care can work to address age-related eyesight problems and enhance eye health. This review discusses the creator, key ingredients, pricing, and most frequently asked questions.

Sight Care is a vision enhancement formula designed to help maintain healthy eyesight through a natural approach. The formula is keenly crafted for people looking for a natural way to enhance their night vision and optimize their eye health. It features a blend of scientifically proven ingredients that allows individuals to maintain healthy vision wellness.

Moreover, the supplement promotes brain and liver function, improves visual awareness, and increases energy levels. Each supplement bottle contains 60 capsules manufactured in a GMP-certified and FDA-registered facility. Therefore, Sight Care complies with the strictest quality, safety, and purity standards. The formula contains potent ingredients that support repairing damaged eye cells and the potential to trigger the production of ARSCs (Adult Repair Stem Cells) in the body.

Sight Care: Try it now, you wont be disappointed!

Sight Care is an eyesight enhancement formula designed by Dr. David Lewis, an eye specialist with 37 years in the eye health industry. According to the specialist, he chose to betray the companies he has worked for in the past and reveal dangerous outcomes that the LASIK industry hides from the public. He created a natural formula to repair vision almost instantly. This is why companies charge exorbitant prices for glasses, earning hundreds or even thousands of dollars.

Dr. David shares a natural and clinically proven way that helps individuals enjoy healthier vision without surgery. According to him, the formula works regardless of how poor your vision or the issue with your eyes. If you find it hard to read road signs, see floaters or dark spots, or struggle with any type of vision issue, Sight Care has you covered.

The doctor claims that the innovative formula will enable you to save thousands of dollars that would have been spent on purchasing eyeglasses. With the Sight Care formula, users can enjoy great vision throughout their lives without the need to wear glasses in the future. Dr. David believes that his 37 years of experience as a specialist backs the effectiveness of the Sight Care formula. According to the doctor, his formula has managed to stop overdependence on contact and eyeglasses. Sight Care has helped 110,000 people between 12 and 93 enjoy clearer vision without using contacts, glasses, or surgery.

Click here to learn more about Sight Care >>>

Sight Care features an innovative formula containing natural ingredients that boost adult repair stem cells. The ability to increase ARSCs is found in specific plants, herbs, minerals, and roots discussed below:

Quercetin is a great medicinal plant used for many years to enhance vision and regenerate the eye significantly. The plant is packed with antioxidants, which provide nutrients that fight free radicals. According to studies, in vitro studies and animal models have shown that the antioxidant and chelating properties of quercetin can protect the lens from oxidative damage and prevent the occurrence of cataracts.

According to a study by scientists, Astaxanthin significantly influences adult repair stem cells. The team of experts found that the tiny sea-based plant has great potential to improve the self-renewal of stem cells. Therefore, the plant instructs the body when to produce new stem cells.

A study reveals more remarkable details about the plant. According to the study, adding Astaxanthin to your diet doesnt just protect the retina against damage but substantially boosts colony formation and proliferation of adult repair stem cells. It also significantly helps improve stem cell potency. Another study revealed that visual awareness substantially improved in groups taking Astaxanthin.

Additionally, a study at an Italian university has shown that the plant significantly reduced macular degeneration. New studies are also coming up with results that back the ability of Astaxanthin to restore eyesight and combat vision issues. Studies show that Astaxanthin supports the increase in stem cells by 26.3%.

N-acetyl-l-cysteine is another important molecule that underwent thorough medical testing to determine its ability to address vision problems. In this clinical study, patients were provided with N-Acetyl-L-Cysteine for three months, and their vision was tested. The test found that 90% of the participants showed enhancements in visual acuity.

With the positive results, the experts confirmed that the NAC plays a key role in addressing vision issues. N-acetyl-l-cysteine is a powerful antioxidant that helps replenish glutathione. Studies have shown that N-Acetyl-L-Cysteine can:

Get Sight Care now while its on sale limited time only!

Zeaxanthin is a plant-based nutrient known to help guard your eyes against age-related health problems. The ingredient supports the regeneration of cells in your eye, which enhances vision sharpness. Zeaxanthin also protects your eyes from potentially harmful blue light resulting from the electronic screens of the devices we use throughout the day, like smartphones. A study on Age-Related Eye Disease Studies found that consistent intake of Zeaxanthin substantially lowers the risk of developing degenerative eye disease and significantly enhances eyesight.

L-lysine is an essential amino acid that helps unblock artery blockages when blended with Vitamin C. This helps restore healthy blood circulation to your eyes. The unique blend was discovered by Linus Pauling, a two-time Nobel Prize winner, and was later approved by Dr. Sydney Bush.

In his clinical trial, Dr. Bush took an image of the retina through a technique known as Cardio-Retinometry. One of the images was taken before treatment, showing artery blockages. The other image was taken after treating the condition using L-lysine and Vitamin C. According to a study, using L-lysine and Vitamin C helps restore eye circulation and drastically reduces the risk of stroke and heart disease.

Lutein is naturally found in certain plants but occurs in large amounts in green leafy vegetables. It is a carotenoid that has anti-inflammatory properties. Studies show the ingredient offers numerous beneficial effects, particularly on eye health. Lutein is found to enhance age-related macular disease causing blindness and vision impairment.

Eyebright is another great herb that has for years been used in traditional medicine to address eye problems, hence the name. A study by European researchers in 2014 found the herb had a real impact on eye conditions. The study proves Eyebright helps fight inflammation in the eye resulting from conjunctivitis and blepharitis. Therefore, the powerful herb will drastically boost your vision to allow you to enjoy the vision clarity of a child.

Bilberry extract is another powerful herb that has for hundreds of years been used for various health benefits, including eye health issues. In WWII, British pilots would eat bilberry jams as they enhanced their night vision, allowing them to hit their enemies accurately.

Recent studies have confirmed a molecule in bilberry, known as anthocyanosides, offers potent anti-inflammatory and antioxidant properties. The molecule has been found to guard your eyes against glaucoma, cataracts, and macular degeneration.

Place your order today by clicking here before stock runs out! >>>

Sight Care comes in three pricing packs. These include:

The manufacturer offers a 180-day money-back guarantee. Therefore, if you are unhappy with the results, you can contact customer care for a full refund.

In conclusion, Sight Care offers a promising natural solution for maintaining healthy vision, backed by clinical trials and formulated by Dr. David Lewis, an experienced eye specialist. It contains a unique blend of carefully selected ingredients that target the root causes of visual impairment. With a 180-day money-back guarantee, Sight Care provides a risk-free option for those seeking to improve their eye health without resorting to invasive procedures.

(Flash Sale) Purchase Sight Care For The Lowest Prices!!

The news and editorial staff of Sound Publishing, Inc. had no role in the preparation of this post. The views and opinions expressed in this sponsored post are those of the advertiser and do not reflect those of Sound Publishing, Inc.

Sound Publishing, Inc. does not accept liability for any loss or damages caused by the use of any products, nor do we endorse any products posted in our Marketplace.

Continued here:
Sight Care Reviews: Supplement Scam or Safe EyeSight Formula to ... - Snoqualmie Valley Record

Association of serum oleic acid level with depression in American … – BMC Psychiatry

By adminNovember 17, 2023Adult Stem Cells

WHO. Depression and other common mental disorders: global health estimates. 2017. https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017%B72-eng.pdf?sequence=1. Accessed 7 Sep 2022.

Chang J-J, Ji Y, Li Y-H, Pan H-F, Su P-Y. Prevalence of anxiety symptom and depressive symptom among college students during COVID-19 pandemic: A meta-analysis. J Affect Disord. 2021;292:24254.

Article CAS PubMed PubMed Central Google Scholar

Daly M, Sutin AR, Robinson E. Depression reported by US adults in 20172018 and March and April 2020. J Affect Disord. 2021;278:1315.

Article CAS PubMed Google Scholar

Baumgart P, Garrick T. Assessment of Depressive Symptoms in Medically Ill Patients. JAMA. 2021;325:24978.

Article PubMed Google Scholar

Calder PC. Functional Roles of Fatty Acids and Their Effects on Human Health. J Parenter Enter Nutr. 2015;39(1_suppl):18S-32S.

Google Scholar

Bazinet RP, Lay S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 2014;15:77185.

Article CAS PubMed Google Scholar

Staiger H, Staiger K, Stefan N, Wahl HG, Machicao F, Kellerer M, et al. Palmitate-Induced Interleukin-6 Expression in Human Coronary Artery Endothelial Cells. Diabetes. 2004;53:320916.

Article CAS PubMed Google Scholar

Zhou X, Liu L, Lan X, Cohen D, Zhang Y, Ravindran AV, et al. Polyunsaturated fatty acids metabolism, purine metabolism and inosine as potential independent diagnostic biomarkers for major depressive disorder in children and adolescents. Mol Psychiatry. 2019;24:147888.

Article CAS PubMed Google Scholar

Ding X, Yang S, Li W, Liu Y, Li Z, Zhang Y, et al. The potential biomarker panels for identification of Major Depressive Disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis. PLoS ONE. 2014;9:e97479.

Article PubMed PubMed Central Google Scholar

McNamara RK, Rider T, Jandacek R, Tso P. Abnormal fatty acid pattern in the superior temporal gyrus distinguishes bipolar disorder from major depression and schizophrenia and resembles multiple sclerosis. Psychiatry Res. 2014;215:5607.

Article CAS PubMed PubMed Central Google Scholar

Assies J, Pouwer F, Lok A, Mocking RJT, Bockting CLH, Visser I, et al. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS ONE. 2010;5:e10635.

Article PubMed PubMed Central Google Scholar

Daley C, Patterson A, Sibbritt D, MacDonald-Wicks L. Unsaturated fat intakes and mental health outcomes in young women from the Australian Longitudinal Study on Womens Heath. Public Health Nutr. 2015;18:54653.

Article PubMed Google Scholar

Li D, Tong Y, Li Y. Associations between dietary oleic acid and linoleic acid and depressive symptoms in perimenopausal women: The Study of Womens Health Across the Nation. Nutrition. 2020;71:110602.

Article CAS PubMed Google Scholar

Bogie JFJ, Grajchen E, Wouters E, Corrales AG, Dierckx T, Vanherle S, et al. Stearoyl-CoA desaturase-1 impairs the reparative properties of macrophages and microglia in the brain. J Exp Med. 2020;217:e20191660.

Article CAS PubMed PubMed Central Google Scholar

Hamilton LK, Moquin-Beaudry G, Mangahas CL, Pratesi F, Aubin M, Aumont A, et al. Stearoyl-CoA Desaturase inhibition reverses immune, synaptic and cognitive impairments in an Alzheimers disease mouse model. Nat Commun. 2022;13:2061.

Article CAS PubMed PubMed Central Google Scholar

Olsen T, Turner C, vreb B, Bastani NE, Refsum H, Vinknes KJ. Postprandial effects of a meal low in sulfur amino acids and high in polyunsaturated fatty acids compared to a meal high in sulfur amino acids and saturated fatty acids on stearoyl CoA-desaturase indices and plasma sulfur amino acids: a pilot study. BMC Res Notes. 2020;13:379.

Article CAS PubMed PubMed Central Google Scholar

Tardiff DF, Lucas M, Wrona I, Chang B, Chung CY, Le Bourdonnec B, et al. Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinsons Disease. Mol Neurobiol. 2022;59:217189.

Article CAS PubMed PubMed Central Google Scholar

Centers for Disease Control and Prevention (CDC). NHANES - NCHS Research Ethics Review Board Approval. 2022. https://www.cdc.gov/nchs/nhanes/irba98.htm. Accessed 5 Aug 2023.

Centers for Disease Control and Prevention (CDC). NHANES - National Health and Nutrition Examination Survey Homepage. 2022. https://www.cdc.gov/nchs/nhanes/index.htm. Accessed 14 Feb 2023.

Lagerstedt SA, Hinrichs DR, Batt SM, Magera MJ, Rinaldo P, McConnell JP. Quantitative determination of plasma c8c26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders. Mol Genet Metab. 2001;73:3845.

Article CAS PubMed Google Scholar

Centers for Disease Control and Prevention (CDC). Fatty Acids - Serum. 2019. https://wwwn.cdc.gov/nchs/data/nhanes/2011-2012/labmethods/FAS_G_MET.PDF. Accessed 14 Feb 2023.

Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:60613.

Article CAS PubMed PubMed Central Google Scholar

Lamers F, Jonkers CCM, Bosma H, Penninx BWJH, Knottnerus JA, van Eijk JThM. Summed score of the Patient Health Questionnaire-9 was a reliable and valid method for depression screening in chronically ill elderly patients. J Clin Epidemiol. 2008;61:67987.

Article PubMed Google Scholar

Thakur VK, Wong JY, Randall JR, Bolton JM, Parikh SV, Mota N, et al. An evaluation of large group cognitive behaviour therapy with mindfulness (CBTm) classes. BMC Psychiatry. 2019;19:132.

Article PubMed PubMed Central Google Scholar

Leavens A, Patten SB, Hudson M, Baron M, Thombs BD, Canadian Scleroderma Research Group. Influence of somatic symptoms on Patient Health Questionnaire-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. Arthritis Care Res. 2012;64:1195201.

Google Scholar

Manea L, Gilbody S, McMillan D. Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. Can Med Assoc J. 2012;184:E1916.

Article Google Scholar

Bot M, Milaneschi Y, Al-Shehri T, Amin N, Garmaeva S, Onderwater GLJ, et al. Metabolomics Profile in Depression: A Pooled Analysis of 230 Metabolic Markers in 5283 Cases With Depression and 10,145 Controls. Biol Psychiatry. 2020;87:40918.

Article CAS PubMed Google Scholar

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:273552.

Article PubMed Google Scholar

He K, Pang T, Huang H. The relationship between depressive symptoms and BMI: 20052018 NHANES data. J Affect Disord. 2022;313:1517.

Article PubMed Google Scholar

Iranpour S, Sabour S. Inverse association between caffeine intake and depressive symptoms in US adults: data from National Health and Nutrition Examination Survey (NHANES) 20052006. Psychiatry Res. 2019;271:7329.

Article CAS PubMed Google Scholar

Shi Y-Y, Zheng R, Cai J-J, Qian S-Z. The association between triglyceride glucose index and depression: data from NHANES 20052018. BMC Psychiatry. 2021;21:267.

Article CAS PubMed PubMed Central Google Scholar

Zhao L, Sun Y, Liu Y, Yan Z, Peng W. A J-shaped association between Dietary Inflammatory Index (DII) and depression: A cross-sectional study from NHANES 20072018. J Affect Disord. 2023;323:25763.

Article PubMed Google Scholar

Stekhoven DJ, Bhlmann P. MissForestnon-parametric missing value imputation for mixed-type data. Bioinforma Oxf Engl. 2012;28:1128.

Article CAS Google Scholar

Dalalyan AS, Thompson P. Outlier-robust estimation of a sparse linear model using 1-penalized Hubers M-estimator. 2019. https://doi.org/10.48550/ARXIV.1904.06288.

Levis B, Benedetti A, Ioannidis JPA, Sun Y, Negeri Z, He C, et al. Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. J Clin Epidemiol. 2020;122:115-128.e1.

Article PubMed Google Scholar

Costantini L, Pasquarella C, Odone A, Colucci ME, Costanza A, Serafini G, et al. Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): A systematic review. J Affect Disord. 2021;279:47383.

Article PubMed Google Scholar

Zeng L, Lv H, Wang X, Xue R, Zhou C, Liu X, et al. Causal effects of fatty acids on depression: Mendelian randomization study. Front Nutr. 2022;9:1010476.

Article PubMed PubMed Central Google Scholar

Aggarwal R, Bhatt DL, Rodriguez F, Yeh RW, Wadhera RK. Trends in Lipid Concentrations and Lipid Control Among US Adults, 20072018. JAMA. 2022;328:73745.

Article CAS PubMed PubMed Central Google Scholar

Rhee SJ, Kim EY, Kim SH, Lee HJ, Kim B, Ha K, et al. Subjective depressive symptoms and metabolic syndrome among the general population. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:22330.

Article PubMed Google Scholar

Kim EY, Kim SH, Ha K, Lee HJ, Yoon DH, Ahn YM. Depression trajectories and the association with metabolic adversities among the middle-aged adults. J Affect Disord. 2015;188:1421.

Article PubMed Google Scholar

Zhang R, Sun J, Li Y, Zhang D. Associations of n-3, n-6 Fatty Acids Intakes and n-6:n-3 Ratio with the Risk of Depressive Symptoms: NHANES 20092016. Nutrients. 2020;12.

Zhang M, Chen J, Yin Z, Wang L, Peng L. The association between depression and metabolic syndrome and its components: a bidirectional two-sample Mendelian randomization study. Transl Psychiatry. 2021;11:633.

Article PubMed PubMed Central Google Scholar

Zhou L, Xiong J-Y, Chai Y-Q, Huang L, Tang Z-Y, Zhang X-F, et al. Possible antidepressant mechanisms of omega-3 polyunsaturated fatty acids acting on the central nervous system. Front Psychiatry. 2022;13:933704.

Article PubMed PubMed Central Google Scholar

Wagner CJ, Musenbichler C, Bhm L, Frber K, Fischer A-I, von Nippold F, et al. LDL cholesterol relates to depression, its severity, and the prospective course. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:40511.

Article CAS PubMed Google Scholar

Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L. Central Administration of Oleic Acid Inhibits Glucose Production and Food Intake. Diabetes. 2002;51:2715.

Article CAS PubMed Google Scholar

Fanning S, Haque A, Imberdis T, Baru V, Barrasa MI, Nuber S, et al. Lipidomic Analysis of -Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell. 2019;73:1001-1014.e8.

Article CAS PubMed Google Scholar

Hamilton LK, Dufresne M, Jopp SE, Petryszyn S, Aumont A, Calon F, et al. Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimers Disease. Cell Stem Cell. 2015;17:397411.

Article CAS PubMed Google Scholar

Thibaut ACM, Rotival M, Gauthier E, Lenoir GM, Boutron-Ruault M-C, Joulin V, et al. Correlation Between Serum Phospholipid Fatty Acids and Dietary Intakes Assessed a Few Years Earlier. Nutr Cancer. 2009;61:5009.

Article PubMed Google Scholar

Yu H, Qin X, Yu Z, Chen Y, Tang L, Shan W. Effects of high-fat diet on the formation of depressive-like behavior in mice. Food Funct. 2021;12:641631.

Article CAS PubMed Google Scholar

See the original post here:
Association of serum oleic acid level with depression in American ... - BMC Psychiatry

Mount Sinai Bioengineers Send Cardiac Muscle Samples Into … – Diagnostic and Interventional Cardiology

By adminNovember 17, 2023Adult Stem Cells

November 16, 2023 Mount Sinais Cardiovascular Research Instituteis sending bioengineered human heart muscle cells and micro-tissues into space for the first time onNASAs29thSpaceXcommercial resupply services mission, which launched Thursday, November 9. The SpaceX CRS-29 mission is sending scientific research to theInternational Space Station(ISS), where the samples will stay for approximately 30 days before returning to Earth.

Through this experiment, Icahn School of Medicine at Mount Sinai researchers aim to gain a better understanding of how cardiac muscle cells, or cardiomyocytes, adapt to extreme biological stresses, and how microgravity and other features of space travel impact cardiomyocyte function. The findings will help scientists find better ways to study heart cell biology in future space experiments.

Understanding the capabilities and limitations of such heart cells to survive is not only important for the health of astronauts, but also a first step toward future efforts in space-based tissue engineering, organoid fabrication, and bioprinting, which are all important players in the emerging economy of biomanufacturing in the microgravity environment known as low Earth orbit.

Mount Sinai is partnering with Space Tango to run this experiment. Space Tango provides access to microgravity for research and development purposes on the ISS. Space Tango will manage Mount Sinais tissues, which will be sealed in individual small-scale experimental containers called cryovials and placed in a larger containment unit known as a CubeLab. These one-milliliter vials also contain cell culture media and additives to help keep the cardiac muscle cells alive for an extended period, with some beating and some chemically arrested to reduce their metabolism and see if their survival is impacted. Once the cargo capsule carrying the research arrives at the ISS, astronauts will place the CubeLab in a dedicated Space Tango facility. After approximately 30 days, astronauts will return the samples to Earth, and Mount Sinai researchers will begin their analyses.

Astronauts commonly experience signs of heart failure during space missions due to extreme conditions that seem to accelerate the aging process. Their symptoms mimic what happens to people on Earth as they age or are bedridden, but at an accelerated pace and a younger age. Results from this experiment could help researchers identify new ways to protect the heart health of astronauts while in space, and to develop new therapies for cardiovascular disease among aging populations on Earth.

This project will help us understand the impact of microgravity and space flight on engineered human heart muscle cells and micro-tissues, and will test for the first time how these highly active beating heart muscle cells adapt to a month of exposure to such extreme conditions. One of the exciting aspects of the experiment is that the samples will be shipped to Mount Sinai alive after they return to Earth, so we can test how the tissues perform when they come back, explains Kevin Costa, PhD, the project leader and an Associate Professor of Medicine (Cardiology) at Icahn Mount Sinai. As we gain a better understanding of how these engineered cardiac cells and tissues function, we can find new ways to help protect astronauts so they can stay in space longer to complete more in-depth exploratory missions. This will also provide clues about how to better protect the hearts of people on Earth from the detrimental effects of aging and inactivity.

Mount Sinai generated these human heart muscle cell samples from induced pluripotent stem cells from a healthy adult donor. The cells are cultured in three distinct configurations: 2D monolayers, 3D spheroids, and 3D elongated cardiac tissue formats. This will test whether the 3D culture conditions, which are more physiologic than 2D cultures, offer a biological advantage for the heart cells.

The goal of the experiment is to assess the ability for our engineered cardiac cells and micro-tissues to survive in a sealed environment in microgravity for 30 days, and to compare the survival characteristics to equivalent samples cultured in our laboratory at Mount Sinais Cardiovascular Research Institute. We are testing to see if microgravity will alter the cardiomyocyte ability to adapt to this enclosed environment, and to see if there are differences in the biology of the cells that are returned from the ISS, adds Dr. Costa. We hope to learn more about the effects of microgravity on human heart cell and tissue biology, and to explore the possibility of performing such studies in a sealed environment that does not require the usual fluidic exchange systems that significantly add to the complexity of doing cell biology in space.

As the cost of space flight continues to drop, and more and more people begin to live and work in space, it will be important to understand how that environment impacts their bodies. Miniaturized bioengineered tissues are great tools for learning about this while minimizing launch costs. We're excited to be able to apply our tools towards the new field of space medicine, and to use microgravity as a model of human aging, says researcher David Sachs, PhD, Assistant Professor of Genetics and Genomic Sciences at Icahn Mount Sinai.

For more information:www.mountsinai.org

Follow this link:
Mount Sinai Bioengineers Send Cardiac Muscle Samples Into ... - Diagnostic and Interventional Cardiology